- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實驗
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細(xì)胞核與細(xì)胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實驗
- Cell Counting Kit-8 (CCK-8)
- 新產(chǎn)品
- 聯(lián)系我們
Cidofovir
別名: HPMPC, GS 0504 中文名稱：西多福韋
Cidofovir通過選擇性抑制病毒DNA的合成而抑制病毒復(fù)制。
Cidofovir Chemical Structure
CAS: 113852-37-2
產(chǎn)品質(zhì)控
批次：
純度：
99.89%
99.89
Cidofovir相關(guān)產(chǎn)品
相關(guān)信號通路圖
細(xì)胞實驗數(shù)據(jù)示例
| 細(xì)胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻(xiàn)信息(PMID) |
|---|---|---|---|---|---|
| HEL cells | Function assay | 3 days | Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM | ||
| HEL cells | Function assay | 3 days | Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50=0.41 μM | ||
| HFF | Proliferation assay | 3 days | Antiproliferative activity against HFF after 3 days by coulter counter assay, EC50=1.9 μM | ||
| HeLaS3 cells | Function assay | 3-5 days | Antiviral activity against Vaccinia virus IHD-J ATCC VR-156 infected in HeLaS3 cells after 3 to 5 days by plaque assay, EC50=18.74 μM | ||
| HSB2 cells | Function assay | 7 days | Antiviral activity against Human herpesvirus 6 GS infected in human HSB2 cells assessed as decrease in viral DNA accumulation after 7 days, EC50=2.7 μM | ||
| HEL cells | Function assay | Compound was tested for anti-viral activity against HSV-1(KOS) in HEL cells, EC50=0.57 μM | |||
| MRC-5 cells | Function assay | Inhibitory activity against cytopathic effect of HSV-2(E 194) in MRC-5 cells, IC50=10 μM | |||
| NHDF cells | Function assay | Inhibitory activity against replication of HCMV in NHDF cells, IC50=0.5 μM | |||
| HFF cells | Function assay | Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction in cytopathogenicity, EC50=3.2 μM | |||
| HFF cells | Function assay | Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction in cytopathogenicity, EC50=7.1 μM | |||
| HFF cells | Function assay | Antiviral activity against vaccinia virus Copenhagen measured as cytopathogenicity in HFF cells, EC50=6.9 μM | |||
| bone marrow cells | Cytotoxicity assay | Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50=10 μM | |||
| HFF cells | Function assay | Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50=0.3 μM | |||
| MRC5 cells | Function assay | Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50=0.3 μM | |||
| UC1B cells | Function assay | Antiviral activity against Murine polyomavirus MN/RDE Toronto in mouse UC1B cells assessed as reduction of virus-induced cytopathogenicity, EC50=13 μM | |||
| african green monkey Vero cells | Function assay | Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50=14.4 μM | |||
| HFF cells | Function assay | Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50=0.22 μM | |||
| HEL cells | Function assay | Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50=0.74 μM | |||
| HEL cells | Function assay | Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.5 μM | |||
| HEL cells | Function assay | Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50=0.3 μM | |||
| HEL cells | Function assay | Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, IC50=0.045 μM | |||
| A549 cells | Function assay | Antiviral activity against Human adenovirus type 11p slobitski infected in A549 cells assessed as inhibition of DNA replication by QPCR assay, EC50=16.5 μM | |||
| HFF cells | Function assay | Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50=6.7 μM | |||
| 點擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Cidofovir通過選擇性抑制病毒DNA的合成而抑制病毒復(fù)制。 |
|---|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | Cidofovir處理培養(yǎng)的細(xì)胞，抑制人類巨細(xì)胞病毒（HCMV）感染。Cidofovir抑制巨細(xì)胞病毒（CMV）蝕斑形成，即使是感染后48小時后加入到細(xì)胞中，作用于Davis和AD-169株時IC50分別為0.9 μg/mL和1.6 μg/mL。[1] Cidofovir也抑制單純皰疹病毒感染。此外，Cidofovir作用于猴腎細(xì)胞，抑制HSV-1誘導(dǎo)的細(xì)胞融合，也抑制HSV-1特異性蛋白的表達(dá)和病毒DNA的合成。[3] |
|||
|---|---|---|---|---|
| 體內(nèi)研究(In Vivo) | ||
| 體內(nèi)研究活性 | Cidofovir 每天按5 mg/kg劑量皮下注射給藥受感染的豚鼠，持續(xù)給藥5天，顯著降低血，脾，肺，和唾液腺中病毒傳染力。Cidofovir處理受感染的動物，顯著降低淋巴細(xì)胞增多和脾臟的平均組織指數(shù)。[2] Cidofovir作用于皮內(nèi)感染與HSV-1或HSV-2的無毛小鼠，抑制所有臨床表現(xiàn)（皮膚損傷，后腿癱瘓，和死亡）。Cidofovir最顯著的特點是感染后到直至第4天才單獨給藥，也顯著抗HSV-1或HSV-2感染。[4] Cidofovir作用于皮下移植小鼠黑色素瘤B16細(xì)胞的C57B16/J小鼠，抑制產(chǎn)生的高度侵襲性的黑色素瘤的生長。[5] |
|
|---|---|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04542252 | Completed | Drug Drug Interaction |
SymBio Pharmaceuticals |
November 9 2020 | Phase 1 |
| NCT01610765 | Withdrawn | Herpes Simplex Virus |
University of Alabama at Birmingham |
January 2016 | Phase 1|Phase 2 |
| NCT01816646 | Completed | Blood And Marrow Transplantation |
M.D. Anderson Cancer Center|Gilead Sciences |
September 2013 | Phase 1 |
| NCT00780182 | Completed | Healthy |
Chimerix|National Institutes of Health (NIH) |
October 2008 | Phase 1 |
|
化學(xué)信息&溶解度
| 分子量 | 279.19 | 分子式 | C8H14N3O6P |
| CAS號 | 113852-37-2 | SDF | Download Cidofovir SDF |
| Smiles | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
Water : 5 mg/mL (17.9 mM) DMSO : Insoluble ( ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Ethanol : Insoluble |
摩爾濃度計算器 |
|
體內(nèi)溶解配方 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 | |||||
實驗計算
動物體內(nèi)配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
